Evolution of treatment modalities for hemophilia A and VWD. A schematic overview of when novel treatment options became available for hemophilia A and VWD. High-purity and recombinant concentrates (orange) arrived 20 years later for VWD compared with hemophilia A. Extended half-life variants, nonfactor therapies, and gene therapy (red) have found their way to the clinic or are in late-stage clinical development for hemophilia A, whereas they are not yet at the horizon with regard to VWD.